356 related articles for article (PubMed ID: 33760171)
1. Knockdown of TMED3 inhibits cell viability and migration and increases apoptosis in human chordoma cells.
Yang J; Huang H; Xiao D; Duan Y; Zheng Y; Chen Z
Int J Oncol; 2021 May; 58(5):. PubMed ID: 33760171
[TBL] [Abstract][Full Text] [Related]
2. TMED3 promotes the progression and development of lung squamous cell carcinoma by regulating EZR.
Xie A; Xu X; Kuang P; Zhang L; Yu F
Cell Death Dis; 2021 Aug; 12(9):804. PubMed ID: 34429402
[TBL] [Abstract][Full Text] [Related]
3. Trafficking protein TMED3 promotes esophageal squamous cell carcinoma.
Yang Y; Liu S; Xie C; Li Q; Gao T; Liu M; Xi M; Zhao L
Biomed J; 2023 Apr; 46(2):100528. PubMed ID: 35358714
[TBL] [Abstract][Full Text] [Related]
4. TMED3 stabilizes SMAD2 by counteracting NEDD4-mediated ubiquitination to promote ovarian cancer.
Chen X; Zhang W; Han X; Li X; Xia L; Wu Y; Zhou Y
Mol Carcinog; 2024 May; 63(5):803-816. PubMed ID: 38411267
[TBL] [Abstract][Full Text] [Related]
5. TMED3 promotes hepatocellular carcinoma progression via IL-11/STAT3 signaling.
Zheng H; Yang Y; Han J; Jiang WH; Chen C; Wang MC; Gao R; Li S; Tian T; Wang J; Ma LJ; Ren H; Zhou WP
Sci Rep; 2016 Nov; 6():37070. PubMed ID: 27901021
[TBL] [Abstract][Full Text] [Related]
6. TMED3 exerts a protumor function in non-small cell lung cancer by enhancing the Wnt/β-catenin pathway via regulation of AKT.
Zhang D; Sun L; Zhang J
Toxicol Appl Pharmacol; 2021 Dec; 433():115793. PubMed ID: 34758370
[TBL] [Abstract][Full Text] [Related]
7. LINC00662 triggers malignant progression of chordoma by the activation of RNF144B via targeting miR-16-5p.
Wang CB; Wang Y; Wang JJ; Guo XL
Eur Rev Med Pharmacol Sci; 2020 Feb; 24(3):1007-1022. PubMed ID: 32096180
[TBL] [Abstract][Full Text] [Related]
8. miR-16-5p inhibits chordoma cell proliferation, invasion and metastasis by targeting Smad3.
Zhang H; Yang K; Ren T; Huang Y; Tang X; Guo W
Cell Death Dis; 2018 Jun; 9(6):680. PubMed ID: 29880900
[TBL] [Abstract][Full Text] [Related]
9. TMED3/RPS15A Axis promotes the development and progression of osteosarcoma.
Xu W; Li Y; Ye X; Ji Y; Chen Y; Zhang X; Li Z
Cancer Cell Int; 2021 Nov; 21(1):630. PubMed ID: 34838013
[TBL] [Abstract][Full Text] [Related]
10. DEPDC1B regulates the progression of human chordoma through UBE2T-mediated ubiquitination of BIRC5.
Wang L; Tang L; Xu R; Ma J; Tian K; Liu Y; Lu Y; Wu Z; Zhu X
Cell Death Dis; 2021 Jul; 12(8):753. PubMed ID: 34330893
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of lncRNA GHET1 inhibits osteosarcoma cells proliferation, invasion, migration and EMT in vitro and in vivo.
Yang W; Shan Z; Zhou X; Peng L; Zhi C; Chai J; Liu H; Yang J; Zhang Z
Cancer Biomark; 2018; 23(4):589-601. PubMed ID: 30475755
[TBL] [Abstract][Full Text] [Related]
12. hsa_circ_0058357 acts as a ceRNA to promote non‑small cell lung cancer progression via the hsa‑miR‑24‑3p/AVL9 axis.
Wei D; Sun L; Feng W
Mol Med Rep; 2021 Jun; 23(6):. PubMed ID: 33880595
[TBL] [Abstract][Full Text] [Related]
13. The FGFR/MEK/ERK/brachyury pathway is critical for chordoma cell growth and survival.
Hu Y; Mintz A; Shah SR; Quinones-Hinojosa A; Hsu W
Carcinogenesis; 2014 Jul; 35(7):1491-9. PubMed ID: 24445144
[TBL] [Abstract][Full Text] [Related]
14. Depleting TMED3 alleviates the development of endometrial carcinoma.
Zhang J; Qi Y
Cancer Cell Int; 2022 Jul; 22(1):231. PubMed ID: 35854294
[TBL] [Abstract][Full Text] [Related]
15. A novel genome-wide in vivo screen for metastatic suppressors in human colon cancer identifies the positive WNT-TCF pathway modulators TMED3 and SOX12.
Duquet A; Melotti A; Mishra S; Malerba M; Seth C; Conod A; Ruiz i Altaba A
EMBO Mol Med; 2014 Jul; 6(7):882-901. PubMed ID: 24920608
[TBL] [Abstract][Full Text] [Related]
16. MiR-876-3p regulates cisplatin resistance and stem cell-like properties of gastric cancer cells by targeting TMED3.
Peng C; Huang K; Liu G; Li Y; Yu C
J Gastroenterol Hepatol; 2019 Oct; 34(10):1711-1719. PubMed ID: 30843262
[TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA LOC554202 modulates chordoma cell proliferation and invasion by recruiting EZH2 and regulating miR-31 expression.
Ma X; Qi S; Duan Z; Liao H; Yang B; Wang W; Tan J; Li Q; Xia X
Cell Prolif; 2017 Dec; 50(6):. PubMed ID: 28963737
[TBL] [Abstract][Full Text] [Related]
18. Y-box binding protein-1 promotes tumorigenesis and progression via the epidermal growth factor receptor/AKT pathway in spinal chordoma.
Liang C; Ma Y; Yong L; Yang C; Wang P; Liu X; Zhu B; Zhou H; Liu X; Liu Z
Cancer Sci; 2019 Jan; 110(1):166-179. PubMed ID: 30426615
[TBL] [Abstract][Full Text] [Related]
19. Activation of Wnt Pathway Suppresses Growth of MUG-Chor1 Chordoma Cell Line.
Şişli HB; Hayal TB; Şenkal S; Bulut E; Kıratlı B; Asutay AB; Şahin F; Bayrak ÖF; Doğan A
Cell Biochem Biophys; 2023 Dec; 81(4):823-837. PubMed ID: 37751039
[TBL] [Abstract][Full Text] [Related]
20. Expression and Therapeutic Potential of SOX9 in Chordoma.
Chen H; Garbutt CC; Spentzos D; Choy E; Hornicek FJ; Duan Z
Clin Cancer Res; 2017 Sep; 23(17):5176-5186. PubMed ID: 28606919
[No Abstract] [Full Text] [Related]
[Next] [New Search]
